Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. - Wikidata - thesis-toulmin - TriplyDB

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

http://www.wikidata.org/entity/Q30235296

about

Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q48295024-7D2A6684-323C-461D-89C2-CA4CD79950E9 Q55283747-DA4A7722-DF58-45C1-8DF3-964937DB7632

P2860

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

http://www.wikidata.org/entity/Q30235296

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

@ast

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

@en

type

label

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

@ast

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

@en

prefLabel

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

@ast

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

@en

P1433

Q30235296-5451FC4E-FD07-43E1-B480-690D1EAFEE2E

P1476

Q30235296-934952E8-E467-4AED-9948-2B6010C81141

P2093

Q30235296-0556B025-981C-41C0-A87C-0D23424B7118

Q30235296-AD4B6B88-4180-40B5-8289-C0F2E579DB30

Q30235296-FE2BCB11-B913-455E-BCF0-F7410DA4EFB2

P2860

Q30235296-0351B787-E6B8-45D8-BED1-4984251228F3

Q30235296-0B9633D8-5D40-4F31-B7D0-5E38D81E55D7

Q30235296-0E573D96-049D-4F0F-BD65-0B3C7D5C55F2

Q30235296-0ED09C3A-5056-4B3B-96D9-070514E4AB72

Q30235296-0EEFF956-FA51-40BC-9B96-EC0BEAE65912

Q30235296-12E1C0F4-8951-4786-A2ED-8E6383C4DF50

Q30235296-14DF302A-4B3E-40E0-AFAB-6FDA0EEB4940

Q30235296-185BD959-D58B-4DC4-B3BA-47B6931F8807

Q30235296-20AAFC43-3BA3-49A0-BEB1-E37840B77316

Q30235296-25548DEA-A8D5-4A3E-ADBD-0FB6FAA5139A

P304

Q30235296-84422479-BD2B-49B5-8812-3B70CF6EEE09

P31

Q30235296-3C07D210-0F99-4F8F-987D-86FC8D076115

P356

Q30235296-5AE51B43-242C-468A-B644-6904A320C21F

P433

Q30235296-4C07620E-ED34-4477-ACDE-725415890E1C

P478

Q30235296-062F037D-28D6-45AA-832E-E77163EBA614

P50

Q30235296-5CC5D80D-73F9-42AC-AD4A-88F393755576

Q30235296-D4F447FE-6E00-4865-83EE-AC5B8423FFF3

P577

Q30235296-27B84159-FF65-4952-9214-772528808C5C

P698

Q30235296-4182ED1E-89E8-4B8D-83F7-059A324CBAEF

P356

17474086.2017.1305264

P1433

Expert Review of Hematology

P1476

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

@en

P2093

Alessia Castellino

http://www.w3.org/2001/XMLSchema#string

Elisa Santambrogio

http://www.w3.org/2001/XMLSchema#string

Maura Nicolosi

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.

P304

289-297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1305264

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Annalisa Chiappella

P577

2017-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28290728

http://www.w3.org/2001/XMLSchema#string